These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12969149)

  • 1. Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability.
    Sweeney WE; Hamahira K; Sweeney J; Garcia-Gatrell M; Frost P; Avner ED
    Kidney Int; 2003 Oct; 64(4):1310-9. PubMed ID: 12969149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor.
    Sweeney WE; Chen Y; Nakanishi K; Frost P; Avner ED
    Kidney Int; 2000 Jan; 57(1):33-40. PubMed ID: 10620185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease.
    Dell KM; Nemo R; Sweeney WE; Levin JI; Frost P; Avner ED
    Kidney Int; 2001 Oct; 60(4):1240-8. PubMed ID: 11576338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats.
    Torres VE; Sweeney WE; Wang X; Qian Q; Harris PC; Frost P; Avner ED
    Kidney Int; 2004 Nov; 66(5):1766-73. PubMed ID: 15496147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGF-related growth factors in the pathogenesis of murine ARPKD.
    MacRae Dell K; Nemo R; Sweeney WE; Avner ED
    Kidney Int; 2004 Jun; 65(6):2018-29. PubMed ID: 15149315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal dysfunction but not cystic change is ameliorated by neonatal epidermal growth factor in bpk mice.
    Nakanishi K; Gattone VH; Sweeney WE; Avner ED
    Pediatr Nephrol; 2001 Jan; 16(1):45-50. PubMed ID: 11198603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor alpha (TGF-alpha) and other targets of tumor necrosis factor-alpha converting enzyme (TACE) in murine polycystic kidney disease.
    Nemo R; Murcia N; Dell KM
    Pediatr Res; 2005 May; 57(5 Pt 1):732-7. PubMed ID: 15774823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.
    Folprecht G; Tabernero J; Köhne CH; Zacharchuk C; Paz-Ares L; Rojo F; Quinn S; Casado E; Salazar R; Abbas R; Lejeune C; Marimón I; Andreu J; Ubbelohde U; Cortes-Funes H; Baselga J
    Clin Cancer Res; 2008 Jan; 14(1):215-23. PubMed ID: 18172273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic analysis of conditionally immortalized cells isolated from the BPK model of ARPKD.
    Sweeney WE; Kusner L; Carlin CR; Chang S; Futey L; Cotton CU; Dell KM; Avner ED
    Am J Physiol Cell Physiol; 2001 Nov; 281(5):C1695-705. PubMed ID: 11600434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.
    Erlichman C; Hidalgo M; Boni JP; Martins P; Quinn SE; Zacharchuk C; Amorusi P; Adjei AA; Rowinsky EK
    J Clin Oncol; 2006 May; 24(15):2252-60. PubMed ID: 16710023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats.
    Torres VE; Sweeney WE; Wang X; Qian Q; Harris PC; Frost P; Avner ED
    Kidney Int; 2003 Nov; 64(5):1573-9. PubMed ID: 14531789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of autosomal recessive polycystic kidney disease in BALB/c-cpk/cpk mice.
    Ricker JL; Gattone VH; Calvet JP; Rankin CA
    J Am Soc Nephrol; 2000 Oct; 11(10):1837-1847. PubMed ID: 11004214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiorgan mRNA misexpression in murine autosomal recessive polycystic kidney disease.
    Gattone VH; Ricker JL; Trambaugh CM; Klein RM
    Kidney Int; 2002 Nov; 62(5):1560-9. PubMed ID: 12371956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease.
    Sweeney WE; Frost P; Avner ED
    World J Nephrol; 2017 Jul; 6(4):188-200. PubMed ID: 28729967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Src inhibition ameliorates polycystic kidney disease.
    Sweeney WE; von Vigier RO; Frost P; Avner ED
    J Am Soc Nephrol; 2008 Jul; 19(7):1331-41. PubMed ID: 18385429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease.
    Gattone VH; Maser RL; Tian C; Rosenberg JM; Branden MG
    Dev Genet; 1999; 24(3-4):309-18. PubMed ID: 10322639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-myc antisense oligonucleotide treatment ameliorates murine ARPKD.
    Ricker JL; Mata JE; Iversen PL; Gattone VH
    Kidney Int; 2002 Jan; 61(1 Suppl):S125-31. PubMed ID: 11841626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional activity of epidermal growth factor receptors in autosomal recessive polycystic kidney disease.
    Sweeney WE; Avner ED
    Am J Physiol; 1998 Sep; 275(3):F387-94. PubMed ID: 9729511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor ameliorates autosomal recessive polycystic kidney disease in mice.
    Gattone VH; Lowden DA; Cowley BD
    Dev Biol; 1995 Jun; 169(2):504-10. PubMed ID: 7781894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased amiloride-sensitive Na+ absorption in collecting duct principal cells isolated from BPK ARPKD mice.
    Veizis EI; Carlin CR; Cotton CU
    Am J Physiol Renal Physiol; 2004 Feb; 286(2):F244-54. PubMed ID: 14559716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.